Related Experiment Video

Updated: Aug 15, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance

D Cilloni1, F Messa, F Arruga

  • 1Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy. daniela.cilloni@unito.it

Leukemia
|November 5, 2005
PubMed

Insights

A new combination therapy using Imatinib and the IKK inhibitor PS1145 shows promise for treating chronic myeloid leukemia (CML) patients resistant to Imatinib alone. This approach targets NF-kB pathways to overcome drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Imatinib is a key therapy for BCR-ABL positive leukemias, but resistance develops in some chronic myeloid leukemia (CML) patients.
  • Constitutive NF-kB/Rel activity is implicated in hematological malignancies, suggesting NF-kB inhibition as an antineoplastic strategy.
  • Targeting kinases in the NF-kB pathway offers a route for tailored therapies.

Purpose of the Study:

  • To investigate the efficacy of the IKK inhibitor PS1145 in CML.
  • To evaluate the combined effect of PS1145 and Imatinib in Imatinib-resistant CML cells and patient samples.

Main Methods:

  • Treatment of CML cell lines and primary bone marrow (BM) cells with PS1145.
  • Assessment of cell proliferation and apoptosis.
  • Combination treatment of resistant cell lines and patient BM cells with PS1145 and Imatinib.

Main Results:

  • PS1145 inhibited proliferation in CML cell lines and primary BM cells.
  • Combining Imatinib with PS1145 enhanced anti-proliferative and pro-apoptotic effects in Imatinib-resistant CML cells and patient BM cells.
  • The combination therapy demonstrated increased inhibition of proliferation and colony growth in resistant CML models.

Conclusions:

  • The IKK inhibitor PS1145 shows activity against CML cells.
  • Combining Imatinib with PS1145 is a rational therapeutic approach for Imatinib-resistant CML patients.
  • This combination strategy offers a potential new treatment option for overcoming CML drug resistance.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...